Global Anthrax Vaccine Market to reach USD XX billion by 2027.Global Anthrax Vaccine Market is valued approximately at USD XX billion in 2020 and is anticipated to grow with a healthy growth rate of more than 7.85% over the forecast period 2021-2027. Anthrax is a deadly disease caused by the spore-forming bacteria Bacillus anthracis. The illness mostly affects cattle and wild game. Humans, on the other hand, can become infected with anthrax bacterium through direct or indirect contact with animals that have anthrax. The bacterium that causes anthrax enters the human body through a skin wound. Furthermore, inhaling bacterial spores and eating infected meat might result in infection. Anthrax symptoms include skin lesions, fever, and vomiting. A three-dose regimen of anthrax vaccinations is used to prevent anthrax. Cell-free protective agent (PA) vaccinations and live anthrax vaccines are two common kinds of anthrax vaccines. The market is driven by the key factors such as increased consumption of undercooked/raw meat and growing burden of anthrax globally. According to the Agricultural Economic Insights (AEI) research, meat consumption in the United States increased from 1970 to 2020. Although the eating patterns of chicken, beef, and pork differ drastically, it raises the risk of anthrax. Furthermore, rise in technological development globally boost the market demand in the forecast years. For instance, In August 2020, Dr. Jamie Benn Felix and the Cook Wildlife Lab team with Texas A&M University College of Veterinary Medicine & Biomedical Sciences conducted a pilot trial for the first oral anthrax vaccination for cattle. However, high cost associated with vaccine may impede market growth over the forecast period of 2021-2027.

The North American market is dominating the market of anthrax vaccine. In terms of revenue, the United States dominates the North American market. The European market is quickly developing because of an increasing patient population, particularly in the United Kingdom and Germany. Asia Pacific and Latin American markets are expected to grow considerably in the foreseeable future. Developing economies such as China and India are expected to contribute to the growth of the Asia Pacific market owing to improved health care infrastructure, economic growth, an increase in the number of insurance payers, the expansion of the private health care sector, and increased awareness in these countries.

Major market player included in this report are:
Colondo Serum Co
Emergent BioSolutions
Indian Immunologicals Limited
Proton Biopharma Ltd
Biogenesis Bago
Merck & Co. Inc.
Zoetis Inc.
Bayer AG
Altimmune (PharmAthene Inc.)
Agrovet




The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Vaccine type:
Live Attenuated Vaccine
Cell Free PA Vaccine
By Application:
Animal Use
Human Use
By Distribution Channel:
Hospitals
Pharmacies
Other Distribution Channels
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027.

Target Audience of the Global Anthrax Vaccine Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors